Literature DB >> 33407692

Global metabolomic and lipidomic analysis reveals the potential mechanisms of hemolysis effect of Ophiopogonin D and Ophiopogonin D' in vivo.

Huan-Hua Xu1,2, Zhen-Hong Jiang3, Cong-Shu Huang2,4, Yu-Ting Sun2, Long-Long Xu2,5, Xiang-Ling Tang2, Hong-Ling Tan2, Zeng-Chun Ma2, Yue Gao6,7.   

Abstract

BACKGROUND: OPD and OPD' are the two main active components of Ophiopogon japonicas in Shenmai injection (SMI). Being isomers of each other, they are supposed to have similar pharmacological activities, but the actual situation is complicated. The difference of hemolytic behavior between OPD and OPD' in vivo and in vitro was discovered and reported by our group for the first time. In vitro, only OPD' showed hemolysis reaction, while in vivo, both OPD and OPD' caused hemolysis. In vitro, the primary cause of hemolysis has been confirmed to be related to the difference between physical and chemical properties of OPD and OPD'. In vivo, although there is a possible explanation for this phenomenon, the one is that OPD is bio-transformed into OPD' or its analogues in vivo, the other one is that both OPD and OPD' were metabolized into more activated forms for hemolysis. However, the mechanism of hemolysis in vivo is still unclear, especially the existing literature are still difficult to explain why OPD shows the inconsistent hemolysis behavior in vivo and in vitro. Therefore, the study of hemolysis of OPD and OPD' in vivo is of great practical significance in response to the increase of adverse events of SMI.
METHODS: Aiming at the hemolysis in vivo, this manuscript adopted untargeted metabolomics and lipidomics technology to preliminarily explore the changes of plasma metabolites and lipids of OPD- and OPD'-treated rats. Metabolomics and lipidomics analyses were performed on ultra-high performance liquid chromatography (UPLC) system tandem with different mass spectrometers (MS) and different columns respectively. Multivariate statistical approaches such as principal component analysis (PCA) and orthogonal partial least square-discriminant analysis (OPLS-DA) were applied to screen the differential metabolites and lipids.
RESULTS: Both OPD and OPD' groups experienced hemolysis, Changes in endogenous differential metabolites and differential lipids, enrichment of differential metabolic pathways, and correlation analysis of differential metabolites and lipids all indicated that the causes of hemolysis by OPD and OPD' were closely related to the interference of phospholipid metabolism.
CONCLUSIONS: This study provided a comprehensive description of metabolomics and lipidomics changes between OPD- and OPD'-treated rats, it would add to the knowledge base of the field, which also provided scientific guidance for the subsequent mechanism research. However, the underlying mechanism require further research.

Entities:  

Keywords:  Hemolysis; Lipidomic; Metabolomic; Ophiopogonin D; Ophiopogonin D'

Year:  2021        PMID: 33407692     DOI: 10.1186/s13020-020-00412-z

Source DB:  PubMed          Journal:  Chin Med        ISSN: 1749-8546            Impact factor:   5.455


  21 in total

1.  The utility of traditional Chinese medicine (Shenmai) in the cardiac rehabilitation after coronary artery bypass grafting: A single-center randomized clinical trial.

Authors:  Chunxiao Zhang; Yaguang Zheng; Tao Chen; Shengyu Wang; Meng Xu
Journal:  Complement Ther Med       Date:  2019-10-10       Impact factor: 2.446

Review 2.  Effects of Shengmai injection add-on therapy to chemotherapy in patients with non-small cell lung cancer: a meta-analysis.

Authors:  Baoqi Duan; Jinsong Xie; Qinglin Rui; Wenxi Zhang; Zhaoqing Xi
Journal:  Support Care Cancer       Date:  2018-03-29       Impact factor: 3.603

3.  Effect of Chinese Medicine on No or Slow Reflow after Percutaneous Coronary Intervention in Myocardial Infarction Patients: A Systematic Review and Meta-Analysis.

Authors:  Xiao-Yu Zhang; Yang Sun; Xin-Yu Yang; Jia-Yuan Hu; Rui Zheng; Shi-Qi Chen; Min Li; Cheng-Yu Li; Yin Jiang; Shuo Liu; Chen Zhao; Yan-Wei Xing; Hong-Cai Shang
Journal:  Chin J Integr Med       Date:  2019-05-15       Impact factor: 1.978

4.  A randomized, double-blind, multicenter, placebo-controlled clinical study on the efficacy and safety of Shenmai injection in patients with chronic heart failure.

Authors:  Shaoxiang Xian; Zhongqi Yang; Jun Lee; Zhiping Jiang; Xiaohan Ye; Luyi Luo; Lili Jin; Tianlun Yang; Suilin Ye; Dongfeng Lu
Journal:  J Ethnopharmacol       Date:  2016-04-01       Impact factor: 4.360

5.  Effect of Shenmai injection on preventing the development of nitroglycerin-induced tolerance in rats.

Authors:  Qian Zhou; Yan Sun; Wangxiao Tan; Xiao Liu; Yuchen Qian; Xianghui Ma; Ting Wang; Xiaoying Wang; Xiumei Gao
Journal:  PLoS One       Date:  2017-04-28       Impact factor: 3.240

6.  Shenmai Injection Protects Against Doxorubicin-Induced Cardiotoxicity via Maintaining Mitochondrial Homeostasis.

Authors:  Lin Li; Jinghao Li; Qilong Wang; Xin Zhao; Dongli Yang; Lu Niu; Yanze Yang; Xianxian Zheng; Limin Hu; Yuhong Li
Journal:  Front Pharmacol       Date:  2020-06-05       Impact factor: 5.810

7.  Comparative Efficacy of Chinese Herbal Injections for Pulmonary Heart Disease: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Kaihuan Wang; Jiarui Wu; Haojia Wang; Xiaojiao Duan; Dan Zhang; Yingzi Wang; Mengwei Ni; Shuyu Liu; Ziqi Meng; Xiantao Zeng; Xiaomeng Zhang
Journal:  Front Pharmacol       Date:  2020-05-07       Impact factor: 5.810

8.  Protective effect of Shenmai injection on doxorubicin-induced cardiotoxicity via regulation of inflammatory mediators.

Authors:  Sheng Zhang; Zhen-Qiang You; Lin Yang; Li-Li Li; You-Ping Wu; Li-Qiang Gu; Yan-Fei Xin
Journal:  BMC Complement Altern Med       Date:  2019-11-19       Impact factor: 3.659

Review 9.  An overview of systematic reviews of shenmai injection for healthcare.

Authors:  Ling-Yan Lu; Guo-Qing Zheng; Yan Wang
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-12       Impact factor: 2.629

10.  Shenmai injection for the treatment of cancer-related fatigue in advanced non-small cell lung cancer patients undergoing chemotherapy: study protocol for a randomized controlled trial.

Authors:  Yushu Zhou; Baiming Zhao; Wanyin Wu; Xiaobing Yang; Shunqin Long; Hong Deng; Wenfeng He; Guiya Liao; Qiuping Li; Zhen Xie
Journal:  Trials       Date:  2018-09-04       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.